Edwards Lifesciences (NYSE:EW) Hits New 1-Year High After Analyst Upgrade

Shares of Edwards Lifesciences Corporation (NYSE:EW) hit a new 52-week high on Friday after Royal Bank Of Canada raised their price target on the stock from $95.00 to $100.00. Royal Bank Of Canada currently has an outperform rating on the stock. Edwards Lifesciences traded as high as $87.61 and last traded at $87.4180, with a volume of 767415 shares trading hands. The stock had previously closed at $85.78.

EW has been the subject of a number of other reports. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research note on Monday, November 3rd. Barclays reissued an “overweight” rating and issued a $99.00 target price (up from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Finally, Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.91.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. 1.29% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences in the first quarter valued at $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the first quarter worth $27,000. Rosenberg Matthew Hamilton bought a new position in Edwards Lifesciences in the second quarter worth $28,000. Finally, True Wealth Design LLC boosted its stake in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

The stock has a market cap of $50.05 billion, a P/E ratio of 37.18, a price-to-earnings-growth ratio of 3.82 and a beta of 0.97. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $80.95 and its 200-day simple moving average is $78.74.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.